- Cann Group (CAN) appoints Peter Koetsier as its new CEO following an extensive search process
- Mr Koetsier will replace Peter Crock, who announced that he would be stepping down as CEO of the company last October
- The incoming CEO has over three decades of general management, marketing and commercial leadership experience in global pharmaceutical companies
- Most recently, he was the Head of Asia Pacific for Ipsen where he developed and led the implementation of a successful growth strategy
- Shares in Cann last traded at 20.5 cents on January 9
Cann Group (CAN) has appointed Peter Koetsier as its new CEO following an extensive
search process.
Mr Koetsier will replace Peter Crock, who announced on October 24, 2022 that he would be stepping down as CEO of the company.
Mr Crock welcomed Mr Koetsier’s appointment and confirmed he will be available to assist in a smooth transition.
With over three decades of general management, marketing and commercial leadership experience in global pharmaceutical companies, Mr Koetsier was most recently the Head of Asia Pacific for French biopharmaceutical company Ipsen.
At Ipsen, he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands.
“Peter is an experienced pharma industry executive with an established track record of driving strong revenue growth in complex and changing environments,” Chairman Allan McCallum said.
“His experience and skills are ideally suited to the needs of Cann and to meeting the opportunities that continue to develop within the medicinal cannabis industry.”
Mr Koetsier’s remuneration package includes a $350,000 base salary plus short term incentives of up to 40 per ent of the fixed remuneration.
He will also be granted 4.5 million options under the Cann Group employee option scheme.
The incoming CEO will commence in his new role from January 16.
Shares in Cann last traded at 20.5 cents on January 9.